-
Mashup Score: 0
January 14, 2021 – The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - NSCLC - ESMO 2020: Lorlatinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC - 4 year(s) ago
By: Julia Fiederlein Posted: Thursday, September 24, 2020 According to Benjamin Solomon, MBBS, PhD, of the Peter MacCallum Cancer Centre, Melbourne, and colleagues, lorlatinib appears to provide longer progression-free survival than crizotinib in patients with ALK-positive non–small cell lung cancer (NSCLC)….
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO20: #lorlatinib versus #crizotinib in first-line treatment of ALK-positive #NSCLC: https://t.co/LQMGFflTN7 #LCSM #JNCCN360 https://t.co/HMX5tMf3HE
-
-
Mashup Score: 0
ALK+ NSCLC patients showed much longer progression-free survival when treated with ensartinib compared with the current standard, crizotinib
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Interim results of the #eXalt3 trial presented at @IASLC #WCLC20 show a 2x increase in PFS for ALK+ #NSCLC patients treated with #ensartinib over #crizotinib. The study remains ongoing but current results look promising for the future #LCSM https://t.co/qQutgRLrgn
-
-
Mashup Score: 0JNCCN 360 - 4 year(s) ago
By: Kelly M. Hennessey, PhD Posted: Thursday, July 16, 2020 The persistence of dormant, drug-resistant cancer cells after surgery and chemotherapy contributes to poor outcomes in patients with ovarian cancer. Robert C. Bast, Jr, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#AACR20: Synergistic effects of #crizotinib and #olaparib in #ovariancancer: https://t.co/6D0ENIt4nU #GynCSM #JNCCN360 https://t.co/tIa3gylJqd
-
#ICYMI: @US_FDA has approved #crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma #lymsm https://t.co/VqFV2RRyVS https://t.co/8SowvIglpy